Document is current

Article History

First Online: 27 July 2022

Disclosure

: C. Slingluff reports research funding to his University from Merck, Celldex, and GlaxoSmithKline; research support in kind to his University from Theraclion and 3M; Scientific Advisory Board role with Immatics (prior), and Curevac (planned); PI role for Polynoma with compensation to his university; and patent royalties as co-inventor of peptides for use in cancer vaccines (patents held by the UVA Licensing and Ventures Group), all outside the submitted work. M.B. Faries reports advisory board participation with Merck, Bristol Myers Squibb, Novartis, Array, Pulse Bioscience, and Sanofi, all outside the submitted work. G.M. Beasley reports relevant financial activities outside the submitted work as a member of the 2020 Regeneron Sanofi advisory board. V. Sondak reports personal fees from Array, Bristol Myers Squibb, Genentech, Merck, Novartis, Pfizer, Regeneron, Replimune, and research funding to his institution from Neogene Therapeutics, outside the submitted work. J.S. Zager reports advisory board participation with Merck, Amgen, and Sanofi Regeneron; speakers bureau participation with Array Biopharma and Sun Pharma; and research work with Amgen, Provectus, Castle Biosciences, and Delcath Systems, all outside the submitted work.